One & One Green Technologies stock soars 100% after IPO debut
Investing.com - H.C. Wainwright has reiterated its Buy rating and $194.00 price target on Biogen (NASDAQ:BIIB), highlighting the company’s promising lupus franchise. The biotechnology company, currently trading at $139.94, shows strong financial health according to InvestingPro analysis, with a "GREAT" overall rating and robust gross margins of 75.6%.
The research firm described Biogen’s lupus treatments litifilimab and dapirolizumab pegol as "compelling, complementary, late stage assets with minimal direct competition in their respective MOAs [mechanisms of action]." With a market capitalization of $20.5 billion and trading at an attractive P/E ratio relative to its growth potential, Biogen appears undervalued based on InvestingPro’s Fair Value analysis.
H.C. Wainwright noted that litifilimab offers dual systemic and skin efficacy with monthly dosing, potentially becoming first-to-market with a cutaneous lupus erythematosus (CLE) label, making it an appealing asset.
The firm pointed out that dapirolizumab pegol has achieved a positive Phase 3 result in systemic lupus erythematosus (SLE) and is progressing through a confirmatory trial (PHOENYCS-FLY) expected to complete in late 2027 or early 2028, with preclinical data suggesting a differentiated pregnancy safety profile.
H.C. Wainwright also expressed confidence that improved clinical trial designs, including tighter inclusion/exclusion criteria and structured steroid taper protocols, help mitigate lupus heterogeneity issues that have challenged previous lupus trials.
In other recent news, Biogen Inc. reported robust financial results for the second quarter of 2025, with earnings per share reaching $5.47, surpassing the forecasted $3.99. The company’s revenue also exceeded expectations, totaling $2.6 billion compared to the projected $2.32 billion. Following this strong performance, Biogen has raised its fiscal year 2025 guidance, anticipating flat revenues at constant currency compared to fiscal year 2024. Additionally, Biogen and Eisai Co., Ltd. have initiated a rolling submission to the U.S. Food and Drug Administration for a new Alzheimer’s treatment, LEQEMBI IQLIK, which has been granted Fast Track Status. Analyst firms have reacted to these developments, with Piper Sandler raising Biogen’s stock price target to $118, citing insights from third-party sales data. Conversely, Morgan Stanley lowered its price target to $144 while maintaining an Equalweight rating. Meanwhile, Oppenheimer reiterated an Outperform rating and set a price target of $205, following Biogen’s second-quarter results. These recent developments highlight Biogen’s ongoing efforts in Alzheimer’s treatment and its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.